

Institut Jules Bordet

Press kit



Contents

A word from the General Management.....	3
The Institut Jules Bordet: High-tech medicine fighting cancer.....	5
Presentation of the Institute.....	5
The Institute's three missions	6
The Institute in figures (2015).....	6
The building of the new Institut Jules Bordet: proud of its past, focused on its future.....	8
The new Institut Jules Bordet – The future Brussels cancer pole	8
The project.....	10
The major strengths of the new Institut Jules Bordet.....	14
The new Institut Jules Bordet in figures.....	16
O.E.C.I. accreditation and designation: The optimising of quality	17
Comprehensive Cancer Centre.....	17
A quality guarantee.....	17
The Institut Jules Bordet's Director of Medical Affairs appointed President of the O.E.C.I.	18
Organisation of European Cancer Institutes – O.E.C.I.	18
Research at the Institut Jules Bordet: fighting and beating cancer.....	20
Clinical research.....	20
Translational research.....	21
Every year, giant steps are taken in the field of research	21
The tumour bank: a collective effort in the service of patients and science	23
Screening and prevention: Preventing and detecting for better care.....	25
Some figures.....	25
Primary or secondary prevention	25
Cancer prevention and screening at the Institut Jules Bordet	26
A personalised prevention plan	26
The Friends of the Institut Jules Bordet: A headstart on cancer.....	27
The missions.....	27
The projects	28
Press Contact – Institut Jules Bordet.....	30

A word from the General Management

The Institut Jules Bordet: The reference centre in the fight against cancer in the 21st century



Stéphane Rillaerts,
General Director



Dr Dominique de Valeriola,
Director Medical Affairs

For many decades now the Institut Jules Bordet has been recognised nationally and internationally for the quality of its cancer patient care, its contribution to research against cancer and the modernity of the treatment methods applied. It is thanks to these efforts that some 60% of cancers correctly detected and treated can today be cured in Belgium.

The Institute is committed to a development programme that must enable it to change dimension and be effective at the level demanded by the fight against cancer in the 21st century. In recent years a number of essential strategic decisions have been progressively implemented:

- the construction of a brand new building in the environment of the Erasmus Hospital and the Faculty of Medicine of the Université Libre de Bruxelles (ULB), in Anderlecht, bringing an increase in surface area from 30,000 to 80,000 m². This will permit a more than 50% increase in care capacity, in the area available for high-tech equipment and in the space allocated to research laboratories; the building is expected to be available in 2020;*
- the consolidation of a medical team and of reference care as well as a management team providing coordinated management of the various departments by guaranteeing the coherence of the means made available to the Institute's missions;*
- the development of an own strategy designed specifically for the fight against cancer. This as part of the overall strategy of the public hospital service in Brussels and in close cooperation with the university vocation of the Erasmus Hospital and the academic missions of the ULB.*

Such is the noble mission that every day motivates more than 1,000 collaborators, each one making their contribution to this complex edifice in a political and institutional context that is continuously developing and with limited financial resources. We thank them most sincerely for their devotion and express our sense of pride in accompanying them on this passionate adventure.

Dr Dominique de Valeriola
Director Medical Affairs



Stéphane Rillaerts
General Director



The Institut Jules Bordet: High-tech medicine fighting cancer

Presentation of the Institute

An integrated multidisciplinary centre, the only one of its kind in Belgium, the Institut Jules Bordet is an autonomous hospital devoted entirely to patients suffering from cancerous diseases.

For more than 75 years the Institut Jules Bordet has been offering its patients diagnostic and therapeutic strategies at the leading edge of progress to prevent, detect and actively fight cancer. The Institute pursues three missions: care, research and teaching. The Institute's international reputation attracts the world's finest experts in the field of cancer while its spirit of innovation has enabled it to participate in the development and discovery of new methods of diagnosis and treatment with the aim of bringing them to the patient as rapidly as possible.

In May 2013 the Institut Jules Bordet was awarded official OECI (Organisation of European Cancer Institutes) accreditation as a Comprehensive Cancer Centre, a quality label reserved for multidisciplinary cancer care institutions that incorporate research and teaching. A first for Belgium.

The Institut Jules Bordet is a member of the Iris and Université Libre de Bruxelles networks and more recently of the Brussels CHU (Brussels University Hospital Centre). With its 160 beds entirely dedicated to cancer, the Institute admits more than 6,000 patients a year, gives 7,500 consultations and provides 12,000 cancer treatments for out-patients. To ensure an adequate response to future demographic and scientific developments, the Institute is building a new Institut Bordet on the campus of the ULB in Erasmus, alongside the Erasmus Hospital. Inauguration is scheduled for 2020.

Read about the Institut Bordet reconstruction project on page 8.

The Institute's three missions

1. Care

The specificity of the Institut Jules Bordet lies in the genuine multidisciplinary of the diagnostic and therapeutic approaches. As soon as the diagnosis is given the treatment decisions are taken following collective reflection and the common accord of specialist doctors and care experts in the type of cancer concerned: oncologists, surgeons, radiotherapists, etc. These therapeutic strategies employ the most modern methods.

2. Research

One fundamental aspect of the Institut Jules Bordet is the way in which research is integrated closely in medical practice, thereby enabling patients to participate in clinical trials of the latest treatments and thus benefit as rapidly as possible from the latest research laboratory discoveries. Many clinical research programmes are conducted in cooperation with other cancer centres and networks, both national and international.

3. Teaching

At the academic level and in the framework of the missions entrusted to it by the Université Libre de Bruxelles, the Institut Jules Bordet is reputed for the quality of its teaching. Every year dozens of medical students and doctors following specialisation courses come to train with our medical teams.

The Institute in figures (2015)

- 96.6% of patients satisfied with their time at the Institute
- 1,000 professionals at your service
- 160 specialist doctors
- 51 doctors training as specialists
- 196 students-doctors trained
- 160 hospitalisation beds
- 5,818 hospitalisations

- 40,094 hospitalisation days
- 15,562 one-day hospitalisation admissions
- 4,807 multidisciplinary oncological consultations
- 5,007 surgical interventions
- 1,970 radiotherapy treatment sessions
- 82,624 medical consultations including 11,031 cancer screening and prevention consultations
- 4,486 psychological and paramedical consultations
- 93 clinical trials open to patients
- 722 patients included in clinical trials
- 199 scientific articles published with an average impact factor of 5.3

The building of the new Institut Jules Bordet: proud of its past, focused on its future.



The new Institut Jules Bordet – The future Brussels cancer pole

After more than 75 years at the heart of Brussels, close to the Porte de Hal, the Institut Jules Bordet is now moving in response to major new developments, including an increase in patient numbers and the need for ever more effective technologies that require more space. The new Institut Jules Bordet will be opening its doors on the U.L.B.'s Erasmus Campus in 2020. As a result of this move, the Institut Jules Bordet will become the reference centre of a genuine Brussels cancer pole as it allies its strengths with the research laboratories of the Université Libre de Bruxelles, the Erasmus Hospital and the hospitals of the I.R.I.S. network.

Alliance against cancer

The reconstruction of the Institut Jules Bordet close to the Erasmus University Hospital and the Faculty of Medicine of the Université Libre de Bruxelles was initiated by the Institute's doctors in the context of a partnership launched in 2005 between the authorities of the U.L.B., the City of Brussels and the C.P.A.S. (social services). Laid down in a framework agreement, this cooperation is based on a number of common guiding strategies, in particular in the field of hospital care, medical teaching and research. The ambition was to create a vast Brussels University Cancer Pole (U.L.B. - Institut Jules Bordet) that would harness the strengths of the partners engaged in the fight against cancer, with the Institut Jules Bordet as reference centre.

To realise this ambition, the hospital-university project must be based on both medical and academic plans. The former involves multidisciplinary care for the patient to guarantee an optimal care pathway within the hospital network thus created. The latter aims to promote and develop the academic nature of each of the institutions.

This new cancer centre will incorporate all the hospital services and most innovative medical technologies essential to leading edge multidisciplinary hospital cancer care as well as major clinical and translational research infrastructures.

Choice of partners

The City of Brussels is supporting the project with its patronage. It is at the basis of the initiative and one of the project's principal champions. Other actors were also involved in the decision-making. The Brussels' C.P.A.S., the Interhospitalière Régionale des Infrastructures de Soins (I.R.I.S.), the Institutes' Medical Board, the U.L.B. and its Faculty of Medicine as well as the Erasmus Hospital all played an active part in developing the project.

The power of attraction of the Brussels University Cancer Pole (I.J.B. - U.L.B.) is dependent on developing a strategy of hospital partnerships and cooperation with the industrial sector, and the pharmaceutical industry in particular. Such cooperation favours both innovation for the benefit of patients and the economic growth of the Brussels Region.

Financing

The reconstruction is being financed by the region (subsidy), federal government (B.M.F. - Financial Means Budget), a subsidy from Beliris (20 million euros) and a substantial contribution from the "Friends of the Institut Jules Bordet" Association for the research laboratories and with a bank loan for the outstanding balance.

The project

The new Institut Jules Bordet building was designed with a threefold aim:

- To best meet the needs of cancer patients and their loved ones, in terms of care quality, well-being and fluidity of movement within the hospital,
- To promote a multidisciplinary cancer care – that is, interaction between doctors, nurses and paramedics from various disciplines in decision-making processes and patient treatment – by designing and organising the building in a way that facilitates and encourages contact between professionals,
- To integrate to a maximum cancer research in patient care by having the research laboratories closely linked to clinical research activities located inside the hospital itself so that doctors and researchers can work together at the patient's bedside.

To best meet these aims, of the 17 projects submitted on the occasion of a European competition, the management team chose the Brunet Saunier - Archi 2000 – TPF joint venture, a grouping of partners from Paris and Brussels that proposed a simple, functional and well-designed building:

- cubic, to encourage multidisciplinary interaction between the care professionals and researchers (rather than a "comb" or "cross" infrastructure that requires systematic reference to a central point)
- compact, to reduce to a maximum the footsteps of patients and professionals and to realise economies of scale,

- transparent and light by virtue of glazed facades and lightwells within the building to guarantee a calming atmosphere and provide a pleasant living environment

Special attention was paid to respecting the environment with the high thermal inertia of the building, intrinsic energy qualities and cogeneration and geothermal solutions. The structure is also modular, flexible and able to integrate highly technical elements typical of a modern hospital.

Building description



The architectural project was studied with the Jacobs engineering office and the actors on the ground with the aim of optimising the care pathways of patients and loved ones as well as the interaction between professionals.

All the flows will depart from an interior street running throughout the building's length, the genuine backbone of the building along which lifts and reception areas for the various services will be located, as well as spaces designed for patients and visitors including a

library, waiting room, cafeteria, health education centre, social service and a special area for the children of patients.

The first underground floor, above a floor containing parking places and logistics rooms, will be entirely dedicated to medico-technical services with medical imaging including radiology (senology, conventional radiology, NMR, CT scan), nuclear medicine (conventional and PET scan), as well as radiotherapy, the medical physics platform and the oncological pharmacy. This floor will be partially lit by external light as only the north-facing façade will be below ground level. Its situation represents an undoubted advantage in terms of radioprotection.

The ground floor, accessible from the esplanade, will be reserved for outpatient consultations, blood tests and one-day hospitalisations.

The first floor will include a lecture theatre for training and scientific meetings as well as offices for care and clinical research staff, enabling them to be rapidly available for both in-patients and out-patients. This space will facilitate multidisciplinary exchange.

The second and third floors are dedicated to hospitalisation. Medical activities (medical oncology and haematology), intensive cancer care, the emergency service for Institute patients as well as a unit for the administration of innovative treatment will be concentrated on one floor. The other will be devoted to surgery and the operation room that will ultimately be the direct extension of the Erasmus operation room when the New Erasmus is built in around 2022.

The technical rooms and administrative areas will occupy the next floor.

The last two floors will be devoted to cellular therapy as well as the clinical and translational research laboratories, today mainly concentrating on haematological, digestive and breast tumours as well as melanoma and tumoural immunology, but with possibilities for extension.

The building will also have an internal logistics function with delivery, arrival and exit bays and warehouses.

Medico-technical aspects

The Institut Jules Bordet already has:

- a sterile unit for the hospitalisation of patients awaiting haematopoietic stem cell transplants
- a cell therapy unit and stem cell banks (haematopoietic cells and umbilical cord blood)
- a unit for the administration of innovative medicines
- a unit for in vivo radioactive treatment
- four particle accelerators using IMRT, VMAT, treatment guided by 3D image, breath-hold technique in breast cancer treatment
- interoperative particle accelerator
- high dose rate radioactive source projector
- a CT simulation scanner
- two magnetic resonance devices
- three CT scanners, one with a double tube – double energy
- ultrasound scanners, one permitting 3D prostatic biopsies and another automated breast examination
- mammography machines including one digital mammography machine with tomosynthesis
- heat-guided radiology tables
- SPECT-CT gamma cameras
- combined PET/CT device
- a surgery robot
- a device permitting the treatment of prostatic tumours using high intensity ultrasound coupled with NMR
- a system of endoscopy with electromagnetic navigation (GPS)
- a laser for mucositis associated with cancer treatments
- two DNA sequencers for genomic characterisation of tumours
- a tumour library containing more than 14,000 tumour samples for research purposes

Most of the devices will be transferred to the new Institut Jules Bordet while some will be replaced. The Institut Jules Bordet generally aims to acquire any innovative new technological device that is pertinent for its patients and is not changing its investment policy ahead of the move.

The new Institut Jules Bordet will work in close cooperation with the Erasmus Hospital immediately after the move, initially through an underground link and then even more so when the two establishments are closely connected in 2022. This partnership concerns nuclear medicine in particular. The project aims to create a nuclear medicine service that is common to the two hospitals.

The major strengths of the new Institut Jules Bordet



The new Institut Jules Bordet brings many benefits to research, patients and visitors, as well as to medical and paramedical staff.

The patient will benefit from:

- An increased reception capacity to meet the needs of future cancer patients whose numbers are increasing. The Institute currently has 160 beds and will have 250 in the new building. A cancer day hospital with 40 beds is also planned.
- Immediate proximity to the services and high technology of the Erasmus hospital
- A public transport network and new car park
- Modern accommodation conditions of hotel standard (Wi-Fi access, ventilation, audiovisual equipment, open areas, etc.)
- More comfort:
 - Reduction in distances and coherence of pathways to reduce number of footsteps, time lost, stress and fatigue
 - View from the bedrooms to the exterior or patio
 - Each bedroom with en-suite shower room
 - Increased availability of single rooms
- Reception facilities for close friends and family
 - Bedroom with accompanying bed
 - Lounges with views over surrounding countryside
 - Close friends and family of patients hospitalised for long periods will have a leisure area and even cooking facilities

The Jules Bordet Institute will benefit from:

- A strengthening of its international reputation
- An academic hospital and the fundamental research laboratories of the U.L.B. Faculty of Medicine in closer proximity to strengthen the synergy between the research poles
- The capacity to undertake more clinical and laboratory research
- An opening up to Europe as a whole and even beyond and not only to Belgian patients
- Facilitated meetings between the hospital's professionals for formal and

informal exchanges

- A compact building on a human scale

Staff will benefit from:

- In addition to the aforementioned benefits, an improved comfort:
 - Spacious cloakrooms adapted to needs
 - A polyvalent room (meetings/relaxation) per unit to enable staff to rest while remaining available in case of an emergency.

The new Institut Jules Bordet in figures

- 250 beds
- 40 one-day hospitalisation beds
- 80,000m²
- 9 floors
- 6 radiotherapy bunkers
- 8 operating theatres
- Project of value 226 million euros (excluding investment in medical devices)

O.E.C.I. accreditation and designation: The optimising of quality

The Institut Jules Bordet was awarded accreditation and designation from the O.E.C.I. as a



Comprehensive Cancer Centre on 15 May 2013. This quality label is reserved for multidisciplinary cancer care institutions providing research, training and patient care and whose activities meet certain quantitative criteria. A first in Belgium.

Comprehensive Cancer Centre



The O.E.C.I. accreditation and designation awarded to the Institut Jules Bordet make it the first recognized Comprehensive Cancer Centre in Belgium. This accreditation programme is based on respect for international quality standards developed specifically by and for European cancer centres and on the basis of an audit procedure.

This quality evaluation programme covers care, research and teaching.

As Dr Dominique de Valeriola, Director Medical Affairs, writes: Obtaining this accreditation *is the result of constant attention accorded by all members of staff at the Institut Jules Bordet to the quality of patient care and the integration of training and research programmes in care activities. O.E.C.I. accreditation is also a recognition of the important contribution made by the Institute Jules Bordet to many projects and discoveries in the field of clinical and translational research in Europe.*"

A quality guarantee

A multidisciplinary and monospecialised centre, the Institut Jules Bordet is recognised for respecting demanding European quality criteria in the field of care and research. It is particularly notable for:

- Multidisciplinary care of a high quality
- Patient-oriented care
- The quality of research and its integration in care activities
- The active role in education and the teaching of professionals
- The constant desire for a continuous improvement in quality

The Institut Jules Bordet's Director of Medical Affairs appointed President of the O.E.C.I.

Doctor Dominique de Valeriola, Director Medical Affairs at the Institut Jules Bordet, was appointed president of the O.E.C.I. in September 2014. Her mandate runs until June 2018 and will have a number of priority objectives, including:

- O.E.C.I. accreditation and designation of European cancer centres. The aim is to ensure a very high quality of care for all cancer patients in Europe and also to eliminate existing disparities between certain cancer centres. Today 29 centres are already designated (17 as Comprehensive Cancer Centres and 12 as Clinical Cancer Centres) and 6 are in the process of being designated.
- The promotion of new developments in the field of biobanks and the molecular biology activities of anatomic pathology laboratories.
- The partnership between patients and their loved ones through patients associations so as to involve them in organising the activities of the cancer centres and permit a mutual strengthening of their demands at European level.
- A strengthening presence of the O.E.C.I. and its members at European level.



Le docteur Dominique de Valeriola,
Directeur Général Médical

Organisation of European Cancer Institutes – O.E.C.I.

Since 1979 the O.E.C.I. has been the sole European network in the fight against cancer. It currently brings together 81 members across Europe.

The network's foremost aim is to improve the quality of care for cancer patients in Europe. To do so, it aims to harmonise the quality of care and research everywhere in Europe so as to bring all institutes engaged in the fight against cancer to the best possible level. To achieve this goal, the O.E.C.I. fulfils a number of missions:

- Compares activities and shares experiences and projects between European cancer centres
- Favours cooperation between centres, in particular for their research activities throughout Europe
- Strengthens links between private and public initiatives
- Transfers best practices tested at European level to Comprehensive Cancer Centres
- Defines quality criteria and results indicators of actions undertaken
- Makes available a database on all Cancer Centres
- Maintains close relations with its US counterpart, the American Association of Cancer Institutes (AACI)

To find out more: www.oeci.eu

Research at the Institut Jules Bordet: fighting and beating cancer



Since its creation, the Institut Jules Bordet has been constantly seeking to understand the cellular mechanisms involved in cancer and to improve treatment of the disease. By working closely together with care professionals and doctors from all backgrounds, researchers at the Institut Jules Bordet are quick to bring the innovations of scientific research to the patient's bedside.

At the Institut Jules Bordet research is both clinical and translational. This activity mobilizes and engages many health professionals as well as patients.

Clinical research

Clinical research consists of the clinical trials or studies we carry out at the Institut Jules Bordet with our partners, academic research centres and pharmaceutical companies. The objectives of these clinical studies are, for example, to test new methods of diagnosis, compare therapeutic strategies or test new and innovative medicines, in particular for cancers

for which there is no effective treatment. Clinical research is only possible with the commitment of the patients. Their participation in clinical trials enables researchers to respond to major research issues.

Translational research

Understanding cancer, seeking the markers to assist in making a diagnosis, predicting the response to certain treatment or making patient prognoses are the principal roles of what is known as translational research. Research of this kind is based on analyses carried out on blood samples and/or tumours removed at the time of a diagnosis or when treating patients – and always with their agreement. Integrated in clinical research, translational research aims to quickly incorporate discoveries in the care offered to patients.

The hospital cooperates with national and international centres and includes research in oncological practice so as to enable patients to benefit from the latest advances in treatment. In this way patients are able to benefit from innovations in technical imaging or drug therapy five to seven years before they are available on the mass market.

Every year, giant steps are taken in the field of research

- A better understanding of the healthy cell and the cancerous cell by virtue of progress in technology, informatics and bio-informatics constitutes the biggest advance in research at the medical level.
- Molecular imaging is the biggest advance in terms of technology.
- Identifying new targets for treatment inside cancer cells represents a new treatment development that makes it possible to introduce more selective and therefore more effective treatment.
- Identifying the abnormal and hereditary genes associated with a very high risk of breast cancer permits a more effective treatment of these patients.
- The development of medicines or procedures designed to interact with the antitumor immunity of patients.
- The creation of a tumour bank, a genuine treasure trove of data that is today one of the biggest sources of tumour samples in Belgium.

As a research institute, the Institut Jules Bordet has set itself the following goals:

- To maintain a competitive research activity of a very high level
- To be leader and innovator at international level in various areas in the fight against cancer
- To render research activities increasingly visible
- To become one of Europe's leading centres in the fight against cancer, rivalling those of the United States

Discover our research units on www.bordet.be

The tumour bank: a collective effort in the service of patients and science



The Institut Jules Bordet has developed a tumour bank (or biobank) around the activities of the Pathological Anatomy Department. A genuine tumour library, it contains tumour samples from more than 1,000 patients and is one of the biggest tumour banks in Belgium.

Samples of biological material (tissue, blood or fluids) taken from the Institute's patients are conserved and made available to the scientists involved in cancer research and treatment. The tumour bank therefore exists thanks to and for the benefit of patients.

This tumour bank permits:

- A better understanding of the mechanism at the origin of the disease
- A better screening and action against cancer

- Introduction of new treatment strategies

The unique nature of each patient means that an adapted treatment is needed. This is facilitated by the tumour bank that therefore plays an essential role in moving towards a personalised medicine.

Since 2012 the Institut Jules Bordet biobank has been the only tumour bank in Belgium with ISO9001 certification that confirms its compliance with numerous quality requirements. Its activities are supported by the National Cancer Plan launched by the Federal Health, Food Chain Security and Environment Service. Since 2013 the tumour bank has also participated in the "Biorepository Proficiency Testing" quality control programme launched by ISBER (International Society for Biological and Environmental Repositories) and that validates and clinically evaluates the biomarkers needed for progress in global health.

Today the team at the tumour bank aim to meet the following challenges:

- To place all data on tumour samples in the virtual catalogue of the National Cancer Register so that they can be consulted by all research teams in Belgium.
- To make the data available to scientists worldwide

The Institut Jules Bordet is well aware of the ethical implications of such an activity. Before the Institute can retain data on a sample obtained from a patient's tissue, the patient must give prior consent. The process remains confidential and the Institute's Ethics Committee and Tumour Bank Committee ensure total protection of patient rights.

Screening and prevention: Preventing and detecting for better care



Some figures

13,600 persons attend our Prevention and Screening Centre every year

67,820 cancers are diagnosed every year in Belgium

3 % of the Belgian population have received a cancer diagnosis within the past 10 years

Primary or secondary prevention

Cancer can occur in anyone. But that does not mean you cannot reduce the risk – by 30% by following a number of simple rules **(primary prevention)**:

- Don't smoke

- Keep slim
- Have a balanced diet
- Practice a physical activity regularly
- Drink alcohol in moderation
- Limit exposure to the sun.

Thanks to screening (**secondary prevention**), some cancers, including some of the most common, can be detected at an early stage, even before any symptoms appear. Screening for cancer is a way to put chance on your side.

Cancer prevention and screening at the Institut Jules Bordet

Our Cancer Screening and Prevention Centre proposes a service for managing the risk of cancer. It is open to all, to people without a particular risk and to persons with a known risk. The approach is multidisciplinary: medical, genetic, social, professional, and psychological.

A personalised prevention plan

First of all, the Cancer Screening and Prevention Centre draws up your risk profile. We then propose a personalised prevention plan. This is a screening strategy adapted to your personal risk situation. We may also recommend certain lifestyle changes (stopping smoking, diet, physical activity). We can help you act on this advice with our Help Centre for Smokers and/or dietitians.

With your agreement we can report back to your GP.

The Friends of the Institut Jules Bordet: A headstart on cancer



The missions

For more than 45 years the Friends of the Institut Bordet a.s.b.l. (non-profit association) has been providing moral and material assistance by financing and supporting research at the Institute on an exclusive basis. In this way the "Friends" have donated almost 12 million euros over the past five years. It is the only association to support the Institute in all its fields of activity and operates thanks to gifts, bequests and the profits from the events it organises.

The projects to be subsidised are chosen on the basis of the evaluation made by independent scientific experts. The "Friends" finance the Institute's research projects directly without intermediary to avoid any loss of resources and energy.

To continue to receive funding for on-going projects, researchers benefitting from financial

aid must provide the association with an activity report. The association remains in daily contact with the scientists so as to obtain a better view of needs and an optimal follow-up of the projects it supports.

"The Friends of the Institut Bordet" association undertakes to:

- Support doctors and researchers at the Institute
- Select and finance research programmes
- Subsidize young researchers through grants
- Fund innovative technological equipment
- Manage the funds raised

The Friends of the Institut Bordet also propose voluntary actions and welcome voluntary workers who undertake two principal missions: the distribution of meals to hospitalised patients; welcoming patients on their arrival at the Institut Jules Bordet.

The projects

To contribute to the development of the Institut Jules Bordet, every year "the Friends" propose a number of actions such as tombolas or gala evenings with the aim of raising funds.

Every year the association also organises the event known as "101 tables pour la vie." Since 2004 about 40 chefs, including starred chefs, make their skills available to cancer research. During this extraordinary day restaurant proprietors each offer a table set for 10 to donors who invite their guests to a surprise meal. The event begins with a gathering of all the guests at Brussels City Hall. After this grand reception the Mayor of Brussels allocates a table to each donor by drawing lots. At this point the evening takes on a gastronomic flavour as the guests sit down to enjoy at the table drawn an exceptional menu prepared by a leading Brussels restaurant. All profits from the event go the association with the aim of financing ever more research programmes at the Institut Jules Bordet.

The hospitalised patients are not forgotten on this occasion. Such starred chefs as Ghislaine Arabian and Yves Mattagne visit the patients at their bedside so that they too can benefit from their skills. Patients are served three star meals in their rooms, prepared with the assistance of

the Institute's dieticians.

Every year a sponsor lends his or her support to the event and participates in distributing the meals at the hospital. Recently Eric-Emmanuel Schmitt and Bernard Yvelès both helped make this festive day a success. This year we will be welcoming another exceptional sponsor, the actress Brigitte Fossey.

To find out more:

www.amis-bordet.be

www.101tables.com

Press Contact – Institut Jules Bordet

Ariane van de Werve

Institut Jules Bordet

Rue Héger-Bordet, 1

1000 Brussels

Tel: +32 2 541 31 39

Mobile: +32 486 17 33 26

E-mail: ariane.vandewerve@bordet.be

www.bordet.be